Indications : התוויות

4.1    Therapeutic indications
Roferon-A is indicated for the treatment of:
-     Condylomata acuminata

-      Hairy cell leukaemia.

-      AIDS patients with progressive, asymptomatic Kaposi's sarcoma who have a CD4 count > 250/mm3.

-      Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. Roferon-A is not an alternative treatment for CML patients who have an HLA-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. It is still unknown whether Roferon-A can be considered as a treatment with a curative potential in this indication.

-      Adult patients with histologically proven chronic hepatitis B who have markers for viral replication, i.e., those who are positive for HBV DNA or HBeAg.


Based on: UK SPC NL/H/0028/11-14/IB/070_Oct2015
-     Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.
The efficacy of interferon alfa-2a in the treatment of hepatitis C is enhanced when combined with ribavirin. Roferon-A should be given alone mainly in case of intolerance or contraindication to ribavirin.

-      Follicular non-Hodgkin’s lymphoma.

-      Advanced renal cell carcinoma.
-      Patients with AJCC stage II malignant melanoma (Breslow tumour thickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.